Maravai Lifesciences Holdings (MRVI) Equity Average: 2021-2025
Historic Equity Average for Maravai Lifesciences Holdings (MRVI) over the last 5 years, with Sep 2025 value amounting to $449.9 million.
- Maravai Lifesciences Holdings' Equity Average fell 35.04% to $449.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $449.9 million, marking a year-over-year decrease of 35.04%. This contributed to the annual value of $683.5 million for FY2024, which is 19.35% down from last year.
- According to the latest figures from Q3 2025, Maravai Lifesciences Holdings' Equity Average is $449.9 million, which was down 9.86% from $499.1 million recorded in Q2 2025.
- Maravai Lifesciences Holdings' Equity Average's 5-year high stood at $902.9 million during Q1 2023, with a 5-year trough of $182.3 million in Q1 2021.
- For the 3-year period, Maravai Lifesciences Holdings' Equity Average averaged around $717.0 million, with its median value being $774.9 million (2024).
- Its Equity Average has fluctuated over the past 5 years, first spiked by 229.12% in 2022, then plummeted by 35.59% in 2025.
- Over the past 5 years, Maravai Lifesciences Holdings' Equity Average (Quarterly) stood at $499.5 million in 2021, then surged by 74.87% to $873.5 million in 2022, then decreased by 3.71% to $841.1 million in 2023, then dropped by 29.26% to $595.0 million in 2024, then plummeted by 35.04% to $449.9 million in 2025.
- Its Equity Average was $449.9 million in Q3 2025, compared to $499.1 million in Q2 2025 and $553.7 million in Q1 2025.